Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ

Information

  • Patent Grant
  • 8920514
  • Patent Number
    8,920,514
  • Date Filed
    Thursday, December 20, 2007
    17 years ago
  • Date Issued
    Tuesday, December 30, 2014
    10 years ago
Abstract
Systems and methods provide intraluminal delivery of a bandage structure within a body lumen or hollow body organ, e.g., for treating an injured gastrointestinal tract or an esophageal hemorrhage in a non-invasive way using endoscopic visualization. The systems and methods can be sized and configured to apply a chitosan bandage structure within a body lumen or hollow body organ, to take advantage of the mucoadhesive, antimicrobial, hemostatic, and potential accelerated wound healing properties of the chitosan material.
Description

This application is related to U.S. patent application Ser. No. 11/084,688, filed on Mar. 17, 2005, entitled “Systems and Methods for Hemmorrhage Control and/or Tissue Repair.”


FIELD OF THE INVENTION

The invention is generally directed to systems and methods to introduce and deploy tissue bandage structures within a body lumen or hollow body organ, such, e.g., as within the gastrointestinal tract.


BACKGROUND OF THE INVENTION

Currently, there exists no overwhelmingly accepted treatment for gastrointestinal, specifically esophageal bleeding with etiology such as; esophageal ulcers, esophagitis, Mallory Weis tears, Booerhave's syndrome, esophageal varices, anastomosis, fistula, and endoscopic procedures.


Electro-cautery and sclerotherapy are two existing treatments for esophageal hemorrhage, however both run a risk of perforation to the esophagus. Electro-cautery requires a large amount of pressure to be applied to the wall of the esophagus and also inherently damages tissue. Sclerotherapy consists of injecting a hardening agent in to the area of the injury with a needle. Clipping is another method of treatment; it consists of a two or three-pronged clip that can be inserted into the mucosa of the esophagus to constrict the area of the bleeding. If applied correctly, clipping is effective in controlling hemorrhage, however clips are difficult to deploy. Often, the clip is not inserted deep enough into the mucosa and sloughs off before the desired time.


SUMMARY OF THE INVENTION

The invention provides systems and methods for applying a bandage structure within a body lumen or a hollow body organ, e.g., for treating an injured gastrointestinal tract or an esophageal hemorrhage.


Another aspect of the invention includes systems and methods for placing a bandage structure within a body lumen or hollow body organ in a non-invasive way using endoscopic visualization.


The systems and methods do not involve the use of any sharp edges or points. The systems and methods do not involve the use of a point pressure, as existing treatment options require. Only moderate circumferential pressure is required to apply the bandage structure. The systems and methods adapt well to tools and techniques usable by gastroenterologists.


The systems and methods can be sized and configured to apply a chitosan bandage structure within a body lumen or hollow body organ, to take advantage of the mucoadhesive, antimicrobial, hemostatic, and potential accelerated wound healing properties of the chitosan material. Drug delivery and cell therapy with a chitosan bandage structure as a delivery matrix are also made possible.


Other features and advantages of the invention shall be apparent based upon the accompanying description, drawings, and claims.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a plane view of an intraluminal delivery system for introducing and applying a bandage structure within a body lumen or hollow body organ.



FIG. 2 is perspective view of the bandage structure that is sized and configured for deployment by the system shown in FIG. 1.



FIGS. 3 to 5 show the rolling of the bandage structure into a low profile condition prior to deployment by the system shown in FIG. 1.



FIGS. 6 to 9 show the placement of a rolled bandage structure upon the expandable delivery structure that forms a part of the system shown in FIG. 1.



FIGS. 10 to 13 show the use of the delivery system shown in FIG. 1 for introducing and applying a bandage structure within a body lumen or hollow body organ.



FIG. 14 shows an optional over-tube that can be used in association with the system shown in FIG. 1.



FIG. 15 shows the system shown in FIG. 1 back-loaded into the working channel of an endoscope.





DESCRIPTION OF THE PREFERRED EMBODIMENT

Although the disclosure hereof is detailed and exact to enable those skilled in the art to practice the invention, the physical embodiments herein disclosed merely exemplify the invention, which may be embodied in other specific structure. While the preferred embodiment has been described, the details may be changed without departing from the invention, which is defined by the claims.


I. The Intraluminal Delivery System



FIG. 1 shows an intraluminal delivery system 10 for introducing and applying a bandage structure 12 within a body lumen or hollow body organ. The delivery system 10 includes a bandage structure 12 and a delivery device 14 that is sized and configured to deliver and deploy the bandage structure 12 at a targeted tissue region within a body lumen or hollow body organ. The delivery device 14 is sized and configured to deploy the bandage structure 12 while preventing it from contacting tissue lining the body lumen or hollow body organ until the desired time of deployment. The delivery device 14 not only provides a barrier between the bandage structure 12 and tissue within the body lumen or hollow body organ during introduction, but also provides a means to deploy the bandage structure 12 into contact with the tissue at the desired time.


As shown in FIG. 1, the delivery device 14 can be sized and configured to accommodate passage over a guide wire 32. In this way, the delivery device 14 can be introduced over the guide wire 32 under direct visualization from an endoscope 50, as FIG. 10 shows. In this arrangement, the guide wire 32 runs next to the endoscope 50 and therefore leaves the working channel of the endoscope 50 free. In an alternative arrangement (see FIG. 15), the delivery device 14 can be sized and configured to be back-loaded through the working channel 52 of an endoscope 50. The working channel 52 of the endoscope 50 thereby serves to guide the delivery device 14 while providing direct visualization.


A. The Tissue Bandage Structure


The size, shape, and configuration of the bandage structure 12 shown in FIG. 1 can vary according to its intended use, which includes taking into account the topology and morphology of the site to be treated and the age/status of the patient (e.g., adult or child). The tissue bandage structure 12 is desirably flexible and relatively thin so that it can be rolled or folded upon itself for deployment in a low profile condition, as FIGS. 2 to 5 show. The tissue bandage structure 12 can be rectilinear, elongated, square, round, oval, or a composite or complex combination thereof. The shape, size, and configuration of tissue bandage structure 12 can be specially formed and adapted to the topology and morphology of the site of application, by cutting, bending, or molding in advance of use.


The tissue bandage structure 12 desirably includes an active therapeutic surface 36 for contacting tissue. The active surface 36 desirably comprises a biocompatible material that reacts in the presence of blood, body fluid, or moisture to become a strong adhesive or glue. The material of the active surface 36 can, alone or in combination with adhesive features, possess other beneficial attributes, for example, anti-bacterial and/or anti-microbial and/or anti-viral characteristics, and/or characteristics that accelerate or otherwise enhance coagulation and the body's defensive reaction to injury.


In one embodiment, the material of the active surface 36 of the tissue bandage structure 12 comprises a hydrophilic polymer form, such as a polyacrylate, an alginate, chitosan, a hydrophilic polyamine, a chitosan derivative, polylysine, polyethylene imine, xanthan, carrageenan, quaternary ammonium polymer, chondroitin sulfate, a starch, a modified cellulosic polymer, a dextran, hyaluronan or combinations thereof. The starch may be of amylase, amylopectin and a combination of amylopectin and amylase.


In a preferred embodiment, the biocompatible material of the active surface 36 comprises a non-mammalian material, which is most preferably poly [β-(1→4)-2-amino-2-deoxy-D-glucopyranose, which is more commonly referred to as chitosan.


The chitosan material is preferred because of the special properties of the chitosan. The chitosan active surface 36 is capable of adhering to a site of tissue injury along a body lumen in the presence of blood, or body fluids, or moisture. The presence of the chitosan active surface 36 stanches, seals, and/or stabilizes the site of tissue injury, while establishing conditions conducive to the healing of the site.


The chitosan material that is incorporated into the active surface 36 can be produced in conventional ways. The structure or form producing steps for the chitosan material are typically carried out from a chitosan solution employing techniques such as freezing (to cause phase separation), non-solvent die extrusion (to produce a filament), electro-spinning (to produce a filament), phase inversion and precipitation with a non-solvent (as is typically used to produce dialysis and filter membranes) or solution coating onto a preformed sponge-like or woven product. The filament can be formed into a non-woven sponge-like mesh by non-woven spinning processes. Alternately, the filament may be produced into a felted weave by conventional spinning and weaving processes. Improved compliance and flexibility can be achieved by mechanical manipulation during or after manufacture, e.g., by controlled micro-fracturing by rolling, bending, twisting, rotating, vibrating, probing, compressing, extending, shaking and kneading; or controlled macro-texturing (by the formation of deep relief patterns) by thermal compression techniques. The tissue bandage structure 12 can also comprise a sheet of woven or non-woven mesh material enveloped between layers of the chitosan material.


The active surface 36 that includes chitosan material presents a robust, permeable, high specific surface area, positively charged surface. The positively charged surface creates a highly reactive surface for red blood cell and platelet interaction. Red blood cell membranes are negatively charged, and they are attracted to the chitosan material. The cellular membranes fuse to chitosan material upon contact. A clot can be formed very quickly, circumventing immediate need for clotting proteins that are normally required for hemostasis. For this reason, the chitosan material is effective for both normal as well as anti-coagulated individuals, and as well as persons having a coagulation disorder like hemophilia. The chitosan material also binds bacteria, endotoxins, and microbes, and can kill bacteria, microbes, and/or viral agents on contact.


B. The Delivery Device


As FIG. 1 shows, the delivery device 14 includes a multi-lumen catheter tube 16 having a proximal end 18 and a distal end 20. The distal end 20 carries an expandable structure 22, which in the illustrated embodiment takes the form of an inflatable balloon. Other non-inflatable, but nevertheless expandable or enlargeable structures, can be used. The proximal end carries an actuator 30 and a coupling 24 which are manipulated in synchrony during operation of the expandable structure 22, as will be described in greater detail later.


The catheter tube 16 can be formed of conventional polymeric materials and include an interior lumen (not shown) that accommodates passage of a guide wire 32. The lumen also passes through the center of the expandable structure 22 as well. This makes it possible to guide the intraluminal deployment of the expandable structure 22 to an injury site within a body lumen or hollow body organ targeted for treatment.


The catheter tube 16 includes another lumen that communicates with the interior of the balloon 22. The proximal end 18 of the catheter tube 16 includes a coupling 24 for coupling an inflation device 26, such as a syringe or the like (see FIG. 1), in communication with the interior of the expandable structure 22. Operation of the inflation device 26 conveys an appropriate inflation medium (e.g., saline) into the expandable structure 22 to cause it to expand.


The catheter tube also includes a movable sheath 28. The sheath 28 comprises a material that is flexible and impermeable to water. A push-pull wire 30 is coupled to the sheath 28, which extends through another lumen within the catheter tube 16 and is coupled to an actuator 30 on the proximal end 18 of the catheter tube 16. Pushing on the actuator 30 advances the sheath 28 distally over the expandable structure 22 (as shown in phantom lines in FIG. 1). Pulling on the actuator 30 withdraws the sheath 28 proximally and free of the expandable structure 22 (as shown in solid lines in FIG. 1).


In use, the tissue bandage structure 12 is sized and configured to be carried about the expandable structure 22 in a generally collapsed condition during introduction within the body lumen or hollow body organ (see FIG. 10). The tissue bandage structure is also sized and configured to be enlarged in response to expansion of the expandable structure 22 (see FIG. 12) for placement into contact with tissue in the body lumen or hollow body organ.



FIGS. 2 to 5 show a representative embodiment of a flexible chitosan bandage structure 12 that can be readily deployed using the delivery device 14 in the manner just described. The bandage structure 12 includes an inert, non-stick, water impermeable coating 34 on a side opposite to the active chitosan surface 36. In use, it is the active chitosan surface 36 that is placed into contact with tissue. The inert, non-stick, water impermeable coating 34 makes it possible to roll or fold the chitosan surface 34 about the expandable structure 22 for deployment without sticking or adhering to the expandable structure 22 or itself.


Prior to intraluminal introduction of the delivery device 14 (see FIGS. 6 and 7), the sheath 28 is withdrawn, and the chitosan bandage structure 12 is mounted about the expandable structure 22, with the active chitosan surface 36 facing outward. In the illustrated embodiment, this is accomplished by wrapping the chitosan bandage structure 12 around the expandable structure 22, with the non-stick coating 34 facing the expandable structure 22. This corresponds to the generally collapsed condition described above, which provides a low profile condition for intraluminal introduction of the chitosan bandage structure 12.


In this arrangement, the flexible bandage structure 12 (see FIGS. 2 to 5) has a rectangular shape with a tab 40 at one end. To secure the bandage in a rolled position about the expandable structure 22 (as shown in FIGS. 6 and 7), the tab can be inserted into a slit 42 formed in the chitosan bandage structure 12. The frictional force between the tab 40 and the walls of the slit 42 are sufficient to hold the bandage structure 12 in a rolled position. However, when pressure is applied from within the rolled bandage structure 12 (as is shown in FIG. 12 and will be described later), the tab 40 slides out of the slit 42 and the bandage structure 12 unfurls. Alternatively, the tab 40 and slit 42 can be replaced by a biodegradable tape with a perforation that will be more reliable in preventing premature deployment or unfurling of the bandage structure 12.


Prior to intraluminal introduction, the sheath 28 is advanced over the bandage structure 12 that has been wrapped about the expandable structure 22 (see FIGS. 8 and 9). As FIG. 9 shows, the distal end of the sheath 28 is closed by a frangible or otherwise releasable securing device 44. The securing device 28 holds the distal end of the sheath 28 closed.


The securing device 44 can be various constructed. It can, e.g., comprise a removable slip-knot that releases when the sheath is withdrawn, or a tearable perforated tab that tears when the sheath is withdrawn, or a ring that slides off or breaks when sheath is withdrawn.


In this position, the sheath 28 prevents contact between the active chitosan surface 36 and the mucosa during introduction until the instance of application. The sheath 28 protects the bandage structure 12 from becoming moist until the sheath 28 is moved proximally to reveal the bandage structure 12.


Prior to insertion into the body lumen (see FIG. 8), the expandable structure 22 is desirably partially enlarged by introduction of the inflating media (e.g., to about 0.25 atm) to create bulbous forms on each side of the bandage structure 12 as shown in FIG. 8. This partial expansion prevents the bandage structure 12 from migrating from the center of the expandable structure 22 during the introduction, but does not otherwise unfurl the bandage structure 12, which remains in the generally collapsed condition.


As will also be described later, when it is desired to deploy the bandage structure 12, the sheath 28 is withdrawn (see FIG. 11) and subsequent expansion of the expandable structure 22 (see FIG. 12) provides enough force to unfurl the bandage structure 12 into contact with an interior wall of the body lumen or hollow body organ.


II. Use of the Delivery System


The delivery system 10 makes possible the deployment of a chitosan bandage structure 12 within a body lumen or hollow body organ under endoscopic visualization, e.g., to treat an injury of the esophagus or other area of the gastrointestinal tract.


As FIGS. 6 to 9 show, the chitosan bandage structure 12 can be wrapped and secured around the expandable structure 22 and enclosed during introduction with the removable sheath 28. The delivery device 12 can be deployed either over a guide wire 32 alongside an endoscope 50 (as FIG. 10 shows) or through the working channel of an endoscope (as FIG. 15 shows). Once the chitosan bandage structure 12 is positioned correctly over an injury site, the removable sheath 28 is pulled back (see FIG. 11) to uncover the chitosan bandage structure 12 for deployment. Subsequent expansion of the expandable structure 22 (see FIG. 12) expands and unfurls the chitosan bandage structure, holding it against the mucosa circumferentially at the site of injury. After an appropriate holding time (e.g., about three minutes), the expandable structure 22 is collapsed, and the delivery device 14 is withdrawn (see FIG. 13), leaving the chitosan bandage structure 12 at the injury site. During the entire procedure, the endoscope 50 provides direct visualization.


As the chitosan bandage structure 12 unfurls, it covers a circumferential section of the body lumen or hollow body organ and adheres to it. The properties of the active chitosan surface 36 serve to moderate bleeding, fluid seepage or weeping, or other forms of fluid loss, while also promoting healing. Due to the properties of the chitosan, the active surface 36 can also form an anti-bacterial and/or anti-microbial and/or anti-viral protective barrier at or surrounding the tissue treatment site within a body lumen or hollow body organ. The active surface 36 (whether or not it contains a chitosan material) can also provide a platform for the delivery of one or more therapeutic agents into the blood stream in a controlled release fashion. Examples of therapeutic agents that can be incorporated into the active surface 36 of the bandage structure 12 include, but are not limited to, drugs or medications, stem cells, antibodies, anti-microbials, anti-virals, collagens, genes, DNA, and other therapeutic agents; hemostatic agents like fibrin; growth factors; Bone Morphogenic Protein (BMP); and similar compounds.


The system 10 thereby makes possible an intraluminal delivery method that (i) locates and identifies the site of injury using an endoscope 50 and correlating video monitor; (ii) passes a guide wire 32 into the site of injury; (iii) positions the distal end of the delivery device 14 over the guide wire 32 (see FIG. 10) at the site of injury while viewing the area with the endoscope 50, which is positioned alongside the catheter tube 14; (iv) when positioned over the site of injury, as confirmed by the endoscope 50, pulls the actuator 30 on the proximal end of the catheter tube 14 (see FIG. 11) to withdraw the sheath 28 (also thereby breaking or otherwise releasing the security device 44) to unsheath and expose the chitosan bandage structure 12; (v) expands the expandable structure 22 (e.g., inflate the balloon) for a prescribed period (e.g., about three minutes) (see FIG. 12) to unfurl the bandage structure 12 and hold the active surface 36 of the bandage structure 12 against mucosa; (vi) after the prescribed holding period, collapses the expandable structure 22 (e.g. deflate the balloon) and removes the delivery device 12 and guide wire 32 (see FIG. 13), while continuing to monitor with the endoscope 50, if desired.


Various modifications of the above-described method can be made. For example (see FIG. 14), between (ii) and (iii), an over-tube 52 may be inserted in the body lumen to serve as a delivery sheath as well as a further water impermeable barrier between the device and the mucosa. As another example (see FIG. 15), the actuator 30 and coupling 24 can be separated from the proximal end of the catheter tube 14, and the catheter tube 14 back-loaded (proximal end first) through the working channel 52 of an endoscope 50. Once back-loaded, the proximal components are re-connected to the catheter tube 14. This arrangement uses the working channel 52 of the endoscope as a delivery sheath, instead of or in combination with a guide wire and/or an over-tube.


The shape, shape, and configuration of the expandable body and the bandage structure 12 can modified to accommodate varying anatomies encountered within a body lumen or hollow body organ, such as the gastrointestinal tract. This expands the possible use of the delivery system 10 greatly. For example, in esophagogastrectomies, an anastomosis between the stomach and the esophagus is created where an asymmetric expandable structure 22 and a bandage structure 12 can be deployed by the system 10 to cover the suture lines of the anastomosis. In addition, the size and shape of the expandable structure 22 can be altered to accommodate deployment of a bandage structure 12 in the duodenum or stomach.


The intraluminal delivery method as described utilizes the catheter-based delivery device 12, as described, to introduce a flexible, relatively thin chitosan bandage structure 12, as described, in an low profile condition and covered with a water impermeable layer to a targeted treatment site within a body lumen or hollow body organ, e.g. to treat esophageal injury. The delivery method prevents the active chitosan surface 36 of the bandage structure 12 from contacting the mucosa until the bandage structure 12 positioned in a desired position over the injury.


III. Conclusion


It has been demonstrated that a therapeutic bandage structure can be introduced and deployed within a body lumen or hollow body organ using an intraluminal delivery system 10 under endoscopic guidance.


It should be apparent that above-described embodiments of this invention are merely descriptive of its principles and are not to be limited. The scope of this invention instead shall be determined from the scope of the following claims, including their equivalents.

Claims
  • 1. A method for intraluminal delivery of a bandage structure within a body lumen or hollow body organ of the gastrointestinal tract or esophagus, comprising the steps of: providing a delivery system comprising: a rolled chitosan bandage having a tab and a slit formed therein, and wherein said chitosan bandage is releasably held in a rolled position by the tab inserted into the slit prior to positioning the bandage within the body lumen or the hollow body organ, has hemostatic properties, and an external active surface that reacts in the presence of a body fluid to become a strong adhesive;an expandable structure supporting said chitosan bandage wherein the tab is inserted into the slit; anda removable sheath enclosing said chitosan bandage;positioning the delivery system within said body lumen or hollow body organ so that the chitosan bandage is positioned over an injury site;removing the removable sheath when the chitosan bandage is positioned over the injury site;expanding the expandable structure to apply pressure from within the chitosan bandage so that the tab slides out of the slit and locates outside an outer surface of the bandage as the rolled chitosan bandage unfurls;adhering the chitosan bandage to said injury site; andremoving the expandable structure.
  • 2. The method according to claim 1, further including endoscopic visualization.
  • 3. The method of claim 1, wherein the delivery system is deployed over a guide wire alongside an endoscope.
  • 4. The method of claim 1, wherein the delivery system is deployed through a working channel of an endoscope.
  • 5. The method of claim 1, wherein the rolled chitosan bandage includes a non-stick coating on a side opposite to the active surface.
  • 6. The method of claim 1, further including holding the chitosan bandage against said injury site for a holding time of about three minutes.
  • 7. The method of claim 1, further including closing the removable sheath using a releasable securing device.
  • 8. The method of claim 1, wherein the body lumen or hollow body organ is an esophagus.
  • 9. The method of claim 8, wherein the esophagus is hemorrhaging.
  • 10. A method for intraluminal delivery of a bandage structure within a body lumen or hollow body organ of the gastrointestinal tract or esophagus, comprising the steps of: providing a delivery system comprising: a rolled chitosan bandage having a tab and a slit formed therein, wherein said chitosan bandage is releasably held in a rolled position by the tab inserted into the slit prior to positioning the bandage within the body lumen or the hollow body organ, has hemostatic properties, and an external active surface that reacts in the presence of a body fluid to become a strong adhesive; andan expandable structure supporting said chitosan bandage;protecting said chitosan bandage from moisture with a removable sheath;enlarging the expandable structure to create bulbous forms on each side of the chitosan bandage structure;positioning the delivery system within said body lumen or hollow body organ so that the chitosan bandage is positioned over an injury site;removing the removable sheath when the chitosan bandage is positioned over the injury site;expanding the expandable structure further so that the tab slides out of the slit and locates outside an outer surface of the bandage as the chitosan bandage unfurls and is held against and adheres to said injury site;covering a circumferential section of the body lumen or hollow body organ with the chitosan bandage;removing the expandable structure; andleaving the chitosan bandage at said injury site.
  • 11. The method of claim 10, wherein the expandable structure is enlarged prior to positioning by the introduction of inflating media to 0.25 atm.
  • 12. The method according to claim 10, further including endoscopic visualization.
  • 13. The method of claim 10, wherein the delivery system is deployed over a guide wire alongside an endoscope.
  • 14. The method of claim 10, wherein the delivery system is deployed through a working channel of an endoscope.
  • 15. The method of claim 10, wherein the rolled chitosan bandage unfurls as the expandable structure applies pressure from within the bandage.
  • 16. The method of claim 10, wherein the chitosan bandage includes a non-stick coating on a side opposite to the active surface.
RELATED APPLICATIONS

This application is a continuation of patent application Ser. No. 11/805,543 filed 23 May 2007, now abandoned, which claims the benefit of provisional patent application Ser. No. 60/802,654filed 23 May 2006.

US Referenced Citations (161)
Number Name Date Kind
2610625 Sifferd et al. Sep 1952 A
2858830 Robins Nov 1958 A
2923664 Cook et al. Feb 1960 A
3551556 Kilment et ai. Dec 1970 A
3632754 Balassa Jan 1972 A
3800792 McKnight et al. Apr 1974 A
3801675 Russell Apr 1974 A
3849238 Gould et al. Nov 1974 A
3902497 Casey Sep 1975 A
3911116 Balassa Oct 1975 A
3954493 Battista et al. May 1976 A
3977406 Roth Aug 1976 A
4040884 Roth Aug 1977 A
4056103 Kaczmarzyk et al. Nov 1977 A
4068757 Casey Jan 1978 A
4094743 Leuba Jun 1978 A
4195175 Peniston et al. Mar 1980 A
4292972 Palwelchak et al. Oct 1981 A
4373519 Errede et al. Feb 1983 A
4394373 Malette et al. Jul 1983 A
4452785 Malette et al. Jun 1984 A
4460642 Errede et al. Jul 1984 A
4501835 Berke Feb 1985 A
4524064 Nambu Jun 1985 A
4532134 Malette et al. Jul 1985 A
4533326 Anthony Aug 1985 A
4541426 Webster Sep 1985 A
4599209 Dautzenberg et al. Jul 1986 A
4651725 Kifune et al. Mar 1987 A
4684370 Barrett Aug 1987 A
4699135 Motosugi et al. Oct 1987 A
4759348 Cawood Jul 1988 A
4772275 Erlich Sep 1988 A
4772419 Malson et al. Sep 1988 A
4833237 Kawamura et al. May 1989 A
4877030 Beck et al. Oct 1989 A
4948540 Nigam Aug 1990 A
4952618 Olsen Aug 1990 A
4956350 Mosbey Sep 1990 A
4958011 Bade Sep 1990 A
4960413 Sagar et al. Oct 1990 A
4973493 Guire Nov 1990 A
4977892 Ewall Dec 1990 A
5006071 Carter Apr 1991 A
5007926 Derbyshire Apr 1991 A
5024841 Chu et al. Jun 1991 A
5035893 Shioya et al. Jul 1991 A
5062418 Dyer et al. Nov 1991 A
5110604 Chu et al. May 1992 A
5116824 Miyata et al. May 1992 A
5147387 Jansen et al. Sep 1992 A
5154928 Andrews Oct 1992 A
5192307 Wall Mar 1993 A
5206028 Li Apr 1993 A
5254301 Sessions et al. Oct 1993 A
5300494 Brode, II et al. Apr 1994 A
5376376 Li Dec 1994 A
5378472 Muzzarelli Jan 1995 A
5411549 Peters May 1995 A
5420197 Lorenz et al. May 1995 A
5441515 Khosravi et al. Aug 1995 A
5443500 Sigwart Aug 1995 A
5449382 Dayton Sep 1995 A
5454719 Hamblen Oct 1995 A
5525710 Unger et al. Jun 1996 A
5527337 Stack et al. Jun 1996 A
5571181 Li Nov 1996 A
5578075 Dayton Nov 1996 A
5593434 Williams Jan 1997 A
5597581 Kaessmann et al. Jan 1997 A
5618299 Khosravi et al. Apr 1997 A
5643596 Pruss et al. Jul 1997 A
5647857 Anderson et al. Jul 1997 A
5649977 Campbell Jul 1997 A
5700476 Rosenthal et al. Dec 1997 A
5738860 Schonfeldt Apr 1998 A
5756111 Yoshikawa et al. May 1998 A
5765682 Bley et al. Jun 1998 A
5797960 Stevens et al. Aug 1998 A
5821271 Roenigk Oct 1998 A
5827265 Glinsky et al. Oct 1998 A
5836970 Pandit Nov 1998 A
5840777 Eagles et al. Nov 1998 A
5858292 Dragoo et al. Jan 1999 A
5858350 Vournakis et al. Jan 1999 A
5952618 Deslauriers Sep 1999 A
5957929 Brenneman Sep 1999 A
5961478 Timmermans Oct 1999 A
5984963 Ryan et al. Nov 1999 A
6042877 Lyon et al. Mar 2000 A
6048360 Khosravi et al. Apr 2000 A
6054122 MacPhee et al. Apr 2000 A
6103369 Lucast et al. Aug 2000 A
6124273 Drohan et al. Sep 2000 A
6156330 Tsukada et al. Dec 2000 A
6162241 Coury et al. Dec 2000 A
6200325 Durcan et al. Mar 2001 B1
6225521 Gueret May 2001 B1
6238431 Asimacopoulos May 2001 B1
6270515 Linden et al. Aug 2001 B1
6406712 Rolf Jun 2002 B1
6448462 Groitzsch et al. Sep 2002 B2
6454787 Maddalo et al. Sep 2002 B1
6485667 Tan Nov 2002 B1
6486285 Fujita Nov 2002 B2
6548081 Sadozai et al. Apr 2003 B2
6548569 Williams et al. Apr 2003 B1
6552244 Jacques et al. Apr 2003 B1
6565878 Schoenfedlt et al. May 2003 B2
6566577 Addison et al. May 2003 B1
6599891 North et al. Jul 2003 B2
6693180 Lee et al. Feb 2004 B2
6726712 Raeder-Devens et al. Apr 2004 B1
6749601 Chin Jun 2004 B2
6750262 Hahnle et al. Jun 2004 B1
6764504 Wang et al. Jul 2004 B2
6827731 Armstrong et al. Dec 2004 B2
6855860 Ruszczak et al. Feb 2005 B2
6863924 Ranganathan et al. Mar 2005 B2
6864245 Vournakis et al. Mar 2005 B2
6992233 Drake et al. Jan 2006 B2
7019191 Looney et al. Mar 2006 B2
7115141 Menz et al. Oct 2006 B2
7371403 McCarthy et al. May 2008 B2
7482503 Gregory et al. Jan 2009 B2
7485138 Fearnot et al. Feb 2009 B2
7491227 Yang Feb 2009 B2
7546812 Eastin et al. Jun 2009 B2
7671102 Gaserod et al. Mar 2010 B2
7763065 Schmid et al. Jul 2010 B2
7820872 Gregory et al. Oct 2010 B2
7850709 Cummins et al. Dec 2010 B2
7897832 McAdams et al. Mar 2011 B2
8043359 Edin Oct 2011 B2
8063265 Beck et al. Nov 2011 B2
20010045177 Harvey et al. Nov 2001 A1
20020035391 Mikus et al. Mar 2002 A1
20020161376 Barry et al. Oct 2002 A1
20040193243 Mangiardi et al. Sep 2004 A1
20050036955 DeGould Feb 2005 A1
20050123581 Ringeisen et al. Jun 2005 A1
20050137512 Campbell et al. Jun 2005 A1
20050143817 Hunter et al. Jun 2005 A1
20050147656 McCarthy et al. Jul 2005 A1
20050240137 Zhu et al. Oct 2005 A1
20060004314 McCarthy et al. Jan 2006 A1
20060008419 Hissink et al. Jan 2006 A1
20060079957 Chin et al. Apr 2006 A1
20060083710 Joerger et al. Apr 2006 A1
20060089702 Cervantes Apr 2006 A1
20060184224 Angel Aug 2006 A1
20060211973 Gregory et al. Sep 2006 A1
20070021703 McCarthy et al. Jan 2007 A1
20070066920 Hopman et al. Mar 2007 A1
20070083137 Hopman et al. Apr 2007 A1
20070237811 Scherr Oct 2007 A1
20070255194 Gudnason et al. Nov 2007 A1
20070255243 Kaun et al. Nov 2007 A1
20070276308 Huey et al. Nov 2007 A1
20080132990 Richardson Jun 2008 A1
20080241229 Li et al. Oct 2008 A1
Foreign Referenced Citations (29)
Number Date Country
0353972 Feb 1990 EP
0477979 Sep 1991 EP
0643963 Mar 1995 EP
1462123 Sep 2004 EP
60-142927 Jul 1985 JP
62-039506 Feb 1987 JP
63-090507 Apr 1988 JP
07-116241 May 1995 JP
11-342153 Dec 1999 JP
2002-233542 Aug 2002 JP
WO 9505794 Mar 1995 WO
WO 9848861 Nov 1998 WO
WO 9902587 Jan 1999 WO
WO 0056256 Sep 2000 WO
WO 02102276 Dec 2002 WO
WO 03047643 Jun 2003 WO
WO 03079946 Oct 2003 WO
WO 03092756 Nov 2003 WO
WO 03101310 Dec 2003 WO
WO 2004047695 Jun 2004 WO
WO 2004060412 Jul 2004 WO
WO 2005062880 Jul 2005 WO
WO 2006049463 May 2006 WO
WO 2006071649 Jul 2006 WO
WO 2007009050 Jan 2007 WO
WO 2007056066 May 2007 WO
WO 2007074327 Jul 2007 WO
WO 2008033462 Mar 2008 WO
WO 2008036225 Mar 2008 WO
Non-Patent Literature Citations (28)
Entry
Park et al., “Platelet derived growth factor releasing chitosan sponge for periodontal bone regeneration.” Biomaterials, vol. 21: 153-159, 2000.
Allan et al., “Biomedical Applications of Chitin and Chitosan.” Chitin, Chitosan, and Related Enzymes—Accademic Press, Inc.: 119-133, 1984.
Anema et al., “Potential Uses of Absorbable Fibrin Adhesive Bandage for Genitourinary Trauma.” World Journal of Surgery, vol. 25: 1573-1577, 2001.
Bégin et al., “Antimicrobial films produced from chitosan.” International Journal of Biological Macromolecules, vol. 26: 63-67, 1999.
Chan et al., “Comparision of Poly-N-acetyl Glucosamine (P-GlcNAc) with Absorbable Collagen (Actifoam), and Fibrin Sealant (Bolheal) for Achieving Hemostasis in a Swine Model of Splenic Hemorrhage.” The Journal of Trauma: 454-458, 2000.
Cole et al., “A pilot study evaluating the efficacy of a fully acetylated poly-N-acetyl glucosamine membrane formulation as a topical hemostatic agent.” Surgery, vol. 126, No. 3: 510-517, 1999.
Kiley, Kevin, “Department of the Army memo.” Jul. 20, 2005.
Kumar, Ravi, “Chitin and chitosan fibres: A review.” Bulletin of Material Science: vol. 22, No. 5: 905-915, Aug. 1999.
Luo et al., “The role of poly(ethylene glycol) in the formation of silver nanoparticles.” Journal of Colloid and Interface Science, vol. 288: 444-448, 2005.
Malette et al., “Chitosan: A New Hemostatic.” The Annals of Thoratic Surgery, vol. 36, No. 1: 55-58, Jul. 1983.
Martin et al., “Medical applications of poly-4-hydroxybutyrate: a strong flexible absorbable biomaterial.” Biochemical Engineering Journal, vol. 16: 97-105, 2003.
Mi et al., “Fabrication and characterization of a sponge-like asymmetric chitosan membrane as a wound dressing.” Biomaterials, vol. 22: 165-173, 2001.
Moody, Robin J., “HemCon bandage stakes claim to soldier's kit bag.” Portland Business Journal, Nov. 4, 2005.
Ohshima et al., “Clinical Application of Chitin Non-Woven Fabric as Wound Dressing.” European Journal of Plastic Surgery, vol. 10: 66-69, 1987.
Ohshima et al., “Clinicai application of new chitin non-woven fabric and new chitin sponge sheet as wound dressing.” European Journal of Plastic Surgery, vol. 14: 207-211, 1991.
Olsen et al., “Bomedical Applicatons of Chitin and its Derivatives.” Chitin and Chitosan: Poceedings from the 4th International Conference on Chitin and Chitosan, 813-829, 1988.
Percot et al., “Optimization of Chitin Extraction from Shrimp Shells.” Biomacromolecules, vol. 4: 12-18, 2003.
Pusateri et al., “Advanced Hemostatic Dressing Development Program: Animal Model Selection Criteria and Results of a Study of Nine Hemostatic Dressings in a Model of Severe Large Venous Hemorrhage and Hepatic Injury in Swine.” The Journal of Trauma, vol. 55: 518-526, 2003.
Sandford, Paul A., “Chitosan: Commercial Uses and Potential Applications.” Chitin and Chitosan: Proceedings from the 4th International Conference on Chitin and Chitosan, 51-69, 1988.
Sandford et al., “Biomedical Applications of High-Purity Chitosan.” Water-Soluble Polymers: Chapter 28: 430-445, 1991.
Sandford, Paul A., “Biomedical Applications of New Forms of Chitin/Chitosan.” Chitin Derivatives in Life Science, 12pp., 1992.
Sondeen et al., “Comparison of 10 Different Hemostatic Dressings in an Aortic Injury.” The Journal of Trauma, vol. 54, No. 2: 280-285, 2003.
Wedmore et al., “A Special Report on the Chitosan-based Hemosatic Dressing: Experience in Current Combat Operations.” The Journal of Trauma, vol. 60: 655-658, 2006.
Wilson, J.R., “The Army's Greatest Inventions.” U.S. Army Materiel Command, pp. 30-37, 2005.
Bendix., “Chemical synthesis of polyactide and its copolymers for medical applications.” Polymer Degradation and Stability, vol. 59: 129-135, 1998.
Schoof et al., “Control of Pore Structure and Size in Freeze-Dried Collagen Sponges.” Journal of Biomedical Material Research, vol. 58: 352-357, 2001.
Wu et al., “Development of In Vitro Adhesion Test for Chitosan Bandages.” Society for Biomaterials 30th Annual Meeting Transactions, 2005, 1pg.
Database WPI, Week 200873 Thomson Scientific, London GB, AN 2008-M34232, XP002695569 & CN 101138648, Mar. 12, 2008.
Related Publications (1)
Number Date Country
20080287907 A1 Nov 2008 US
Provisional Applications (1)
Number Date Country
60802654 May 2006 US
Continuations (1)
Number Date Country
Parent 11805543 May 2007 US
Child 12004297 US